ArticleFrontiers in global women's health2025
Global, regional and national burden of inflammatory bowel disease in females from 1990 to 2021: an analysis of the global burden of disease study 2021.
Article in Frontiers in global women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Burden and Long-Term Trends of Viral Hepatitis in China: A National and Provincial Analysis.Current medical science · 2026Article
- School and School-Related Experiences of Children and Adolescents With Inflammatory Bowel Disease: A Scoping Review.Child: care, health and development · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: The global incidence of inflammatory bowel disease (IBD) has markedly increased over past several decades. Gender-specific differences have been observed in the epidemiology, manifestation, and prognosis of IBD. Given these distinctions, a focused analysis of the latest epidemiological trends in female patients is essential for advancing targeted healthcare. Methods: A comprehensive analysis of IBD incidence, mortality, and disability-adjusted life years (DALYs) in females was performed using data from the Global Burden of Disease (GBD) study from 1990 to 2021, with stratifications by age, region, country, and sociodemographic index (SDI). Results: In 2021, approximately 187,134 females were diagnosed with IBD globally. Incidence rates were highest among females aged 30-60, with disease burden increasing significantly with age in older populations. Geographically, High-Income North America had the highest IBD burden in females in 2021, while Australasia experienced the most significant increase from 1990 to 2021 (estimated average percentage changes (EAPC) = 1.13, 95% CI 0.8-1.46). Nationally, 75 countries and territories showed upward trends in the age-standardized DALYs (disability-adjusted life years) rate (ASDR), with the steepest rise observed in Mauritius (EAPC = 2.28, 95% CI 0.82-3.76). DALYs due to IBD in females also increased across all SDI regions, showing a positive correlation between SDI and ASDR. Conclusions: The global burden of IBD in females has significantly risen from 1990 to 2021, with marked age, regional and SDI-based differences. Incidence rates are higher in high-income regions in Europe and North America, with the sharpest increases observed in East Asia, highlighting the need for age and region-specific IBD management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.